After treatment, the methylation level of the PAX2 promoter decreased in endometrial cancer cell lines (HEC-1A: from 94.6% to 55.4%, RL95-2: from 59% to 48%, HEC-1B: from 96% to 66%. This evidence concerns the gene PAX2 and endometrial cancer.